PIK3CA and colorectal cancer: While patients whose tumours did not carry a PIK3CA mutation had no observed benefit from aspirin therapy in these trials, patients whose tumours carry PIK3CA mutations had a HR of 0.11–0.18 for colorectal cancer-specific death.